The CCK-BR antagonist, proglumide, altered the HCC tumor microenvironment by decreasing fibrosis and increasing CD8+ T cells, rendering the tumor then responsive to immune checkpoint antibody therapy. This evidence concerns the gene CD8A and hepatocellular carcinoma.